FDA Approves Novartis’ Meningitis Vaccine in Children

Novartis announced Monday that it received approval from the US Food and Drug Administration for the use of Menveo (Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in individuals 2 to 10 years of age.
myScience